LTR Pharma Limited (ASX:LTP) Expands SPONTAN Access Nationwide
Distribution Expansion
LTR Pharma Limited (ASX:LTP) has made SPONTAN® available through TerryWhite Chemmart’s network of over six hundred pharmacies nationwide. This expansion marks a pivotal milestone in the company’s strategy to enhance patient access under its partnership with Symbion Pty Ltd.
Commercial Packaging and Prescription Process
The company has developed new barcoded commercial packaging for SPONTAN, facilitating pharmacy integration and future telehealth pathways. Patients with prescriptions from authorised healthcare professionals can now fill them at participating TerryWhite Chemmart, Pharmacy Choice, or healthSAVE pharmacies under the TGA’s Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS).
Operational Implementation
Following the January 2025 distribution agreement with Symbion, LTR Pharma has integrated inventory management systems, implemented TGA-compliant tracking protocols, and completed pharmacist training. The company will also present at the TerryWhite Chemmart Masterclass in June 2025 to educate pharmacists on SPONTAN dispensing.
Real-World Data Collection
The nationwide rollout enables LTR Pharma to collect real-time data on SPONTAN usage, supporting regulatory strategies and preparations for the commercial launch in Australia and the planned US launch of ROXUS in 2026.
Executive Comments
LTR Pharma Executive Chairman, Lee Rodne, stated, “The national rollout of SPONTAN through TerryWhite Chemmart and other pharmacy networks represents the implementation of our Symbion partnership and delivers convenient physical access points for patients across the country. This milestone supports our commitment to improving the availability of SPONTAN across Australia while we progress our regulatory pathway. Patients can now have their SPONTAN prescriptions filled at participating pharmacies nationwide, providing a direct pathway from healthcare professional to pharmacy dispensing.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
